Despite Softness in Q1, Qiagen Expects HPV Business to Bounce Back This Year

The company recently achieved 40 percent market penetration in the US with its HPV tests, and CEO Peer Schatz said 80 percent penetration in the US is a "conservative and reasonable estimate."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.